Mylan (MYL) Gains Early After Taking Action on EpiPen Pricing
- Top 10 News for 10/24 - 10/28: AT&T (T), Time Warner Make it Official; Margins Hamper Apple's Q4; Mergers Aplenty
- Wall St. falls as FBI to review more Clinton emails
- Clinton email problem resurfaces as FBI announces review
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
After dropping sharply over the past few sessions on headline risk related to EpiPen pricing, Mylan (NASDAQ: MYL) shares are gaining 3% early after the company announced plans to reduce patient cost through savings card which will cover up to $300 for their EpiPen 2-Pak.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citron Research is long Mylan (MYL) - CNBC
- Check Point Software Technology (CHKP) 30-day volatility flat into Q3
- Dean Foods (DF) November volatility increases on sharp rally
Create E-mail Alert Related CategoriesTrader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!